Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest linezolid Stories

2014-04-03 12:27:08

Lipoglycopeptides Dalvance and Oritavancin Will Find Favorable Uptake as Convenient Outpatient Anti-MRSA Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., April 3, 2014 /PRNewswire/ -- Decision Resources Group finds that following its launch, Cubist's second generation oxazolidinone Sivextro will be highly differentiated from other anti-MRSA (methicillin-resistant Staphylococcus aureus) agents for the treatment of complicated skin and skin structure infections...

2013-11-19 08:26:14

New Long-Acting Agents Are Poised to Challenge the Position of IV Vancomycin and Cubist's Cubicin in the OPAT Market, According to a New Report from Decision Resources Group BURLINGTON, Mass., Nov. 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than three-quarters of surveyed physicians anticipate prescribing Durata's dalbavancin and The Medicines Company's oritavancin as...

New Treatment May End Dangerous MRSA Superbug Infections
2013-11-15 10:44:19

Rebekah Eliason for redOrbit.com – Your Universe Online One of the most significant health threats people face today is antibiotic resistant bacteria. A new study by Professor of Biology Kim Lewis presents a groundbreaking method for treating and eliminating the deadly bacterium methicillin resistant staphylococcus aureus, commonly known as MRSA. Referred to as a “superbug”, MRSA infects a staggering 1 million Americans every year. This bacteria is especially deadly as it leads to...

2013-11-12 00:22:22

AUSTIN, TX and TORONTO, ON, Nov. 12, 2013 /PRNewswire/ - Affinium Pharmaceuticals ("Affinium") announced today that the U.S. Food and Drug Administration (FDA) has designated Affinium's Phase 2 antibiotic, AFN-1252, as a Qualified Infectious Disease Product (QIDP) for use in acute bacterial skin and skin structure infections (ABSSSI) based on the Phase 2 study recently completed in that indication. The QIDP designation is expected to enable Affinium to benefit from FDA regulatory...

2013-10-17 08:30:19

Availability of Intravenous and Oral Formulations Could Help Differentiate Drugs in the Highly Competitive HT-MRSA Market, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 17, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the hospital-treated MRSA (HT-MRSA) drug market will grow modestly over the next decade from approximately $900 million in 2012 to $1...

2013-10-16 12:24:22

Demonstrating Pharmacoeconomic Advantages Over Competitors Could Favor Formulary Inclusion of Novel Antibiotics, According to a New Report from Arlington Medical Resources EXTON, Pa., Oct. 16, 2013 /PRNewswire/ -- Arlington Medical Resources finds that antibiotic cost-related attributes such as drug price and administration costs, followed by pathogen coverage and efficacy, are the most important factors that influence hospital formulary decision making. Additionally, surveyed...

2013-09-04 20:21:55

AUSTIN, TX and TORONTO, ON, Sept. 4, 2013 /PRNewswire/ - Affinium Pharmaceuticals ("Affinium") announced today that it has initiated dosing in a Phase 1 intravenous (IV) clinical trial of its new antibiotic prodrug, AFN-1720.  AFN-1720 is the prodrug of the active drug, AFN-1252.  Initiation of this IV clinical study follows Affinium's 2012 successful oral Phase 2a clinical study demonstrating excellent safety, efficacy and tolerability in acute bacterial skin and skin structure...

2013-08-22 04:21:55

-- Funds U.S. Development of MRX-I Next-Generation Antibiotic -- HAYWARD, Calif. and SHANGHAI, Aug. 22, 2013 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced it raised $25 million in Series B financing. Led by BVCF, a private equity and growth fund specializing in the life sciences industry, the round also includes existing investors Morningside Group and Devon Park Bioventures. Proceeds...

2013-04-26 20:21:38

- Phase 2 study of patients with gonococcal infections shows 100 percent were treated successfully CHAPEL HILL, N.C., April 26, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it will present data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Berlin,...

2013-04-04 08:29:31

Studies find prior authorization programs are associated with increased quality of care and cost effectiveness; 30- versus 90- day supply claims reduce specialty medication waste SAN DIEGO, April 4, 2013 /PRNewswire/ -- Prime Therapeutics (Prime), a leading pharmacy benefit manager, will be presenting three new studies at the Academy of Managed Care Pharmacy (AMCP)'s 25(th) Annual meeting & Expo in San Diego today. Studies concluded that UM programs may increase the quality of...


Latest linezolid Reference Libraries

0_4d46cc72a490344d44ba78359f528175
2011-04-26 21:07:20

Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...

0_71ad70ea6f0948a7e84406e760c7f5a4
2011-04-15 14:36:05

Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...

More Articles (2 articles) »